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RESEARCH ARTICLE

Assessment of Predictive Factors of Hepatic Steatosis
Diagnosed by Vibration Controlled Transient
Elastography (VCTE) in Chronic Hepatitis C
Virus-Infected Patients
Yuvaraj Singh*, Maya Gogtay1, Susant Gurung2, Nitin Trivedi3, George M. Abraham4
Department of Medicine, Saint Vincent Hospital, Worcester, MA, USA

Abstract
This retrospective, cross-sectional study aimed to evaluate the predictive factors of moderate/severe hepatic steatosis
diagnosed by vibration-controlled transient elastography (VCTE). It included 158 adult patients with suspected nonalcoholic fatty liver disease (NAFLD) evaluated by VCTE in an outpatient setting of a community-based teaching
hospital. Patients with signiﬁcant alcohol consumption, oral contraceptive use, hepatitis B disease, autoimmune hepatitis, and primary biliary cirrhosis were excluded. Steatosis was categorized as S0eS1 (mild) and S2eS3 (moderate/severe) based on the controlled attenuation parameter (CAP) score. Results demonstrated the mean values of BMI
(p ¼ 0.001), kiloPascals [kPa] (ﬁbrosis) raw score (p ¼ 0.009), obesity (p ¼ 0.001), diabetes mellitus [DM] (p ¼ 0.014), and
comorbidities status [chronic hepatitis C(HCV), DM, obesity, HCVþDM] (p ¼ 0.028) were signiﬁcantly different between the two arms of the study viz. S0eS1 (mild) and S2eS3 (moderate/severe). A multinomial logistic regression
analysis of the comorbidities associated with hepatic steatosis revealed a good level of prediction (R2-0.584) for hepatic
steatosis. Of all the variables analyzed, obesity was the most impactful vavriable. Furthermore, the ¡2 log-likelihood of
the regressed model in patients with HCV and hepatic steatosis did not show a signiﬁcant correlation when adjusted for
obesity. Obesity had a signiﬁcant independent association with steatosis (chi-square value ¼ 52, df ¼ 12). Interestingly,
DM independently predicted a weak association with steatosis (chi-square value ¼ 0.825, df ¼ 3). In conclusion, our
study demonstrates that hepatic steatosis is independently associated with metabolic parameters like obesity and DM.
Management of these risk factors in patients with HCV may be vital to reducing the risk of steatosis and progression to
ﬁbrosis.
Keywords: Hepatitis C virus (HCV), Steatosis, VCTE, CAP, Obesity, NAFLD

1. Introduction

B

oth hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD) are signiﬁcant causes of liver-related morbidity and mortality. HCV is a signiﬁcant cause of chronic liver
disease, with about 170 million people infected
worldwide. The severity of the disease varies widely

from asymptomatic chronic infection to cirrhosis
and hepatocellular carcinoma (HCC).1 Hepatic
steatosis is deﬁned as excessive fat accumulation in
the liver (>5% involvement). It is currently the most
common cause of chronic liver disease worldwide.2,3
In chronic HCV patients, the prevalence of steatosis ranges from 40% to 86% (mean, 55%).4,5 Most
patients (78%) have mild steatosis affecting less than
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30% of hepatocytes. Thus, steatosis occurs more
frequently in patients with HCV (55%) than in the
general population (20%e30%) of adults in the
western world.6 In non-diabetic, overweight patients, moderate or severe steatosis is present in
only 10%e15% of genotypes 1 and 4 as compared
with 40% of genotype 3 patients.7,8
Frequency of NASH ranged from 12.6% to 30.4%
among obese patients. The rate of disease progression was associated with age, ethnicity, genetics, and
presence of comorbidities (e.g obesity, T2DM, and
hypertension).9 Among 10 studies that estimated the
prevalence of NASH, the global prevalence of
NASH among individuals with T2DM was 37.3%
(95% CI 24.7e50.0%). Seven studies estimated the
prevalence of advanced ﬁbrosis in patients with
NAFLD and T2DM to be 17.0% (95% CI 7.2e34.8).10
Conventional ultrasonography (USG) is a noninvasive, cost-effective, rapid technique that detects
patients with chronic liver diseases; however, it
cannot quantify the degree of steatosis independently.9,10 Vibration-controlled transient elastography (VCTE) is a novel, non-invasive method for
ﬁbrosis staging using liver stiffness measurement.11
Furthermore, through the embedded controlled
attenuation parameter (CAP) tool, VCTE can
simultaneously assess liver steatosis by estimating
the total ultrasonic attenuation.12 Ultrasound
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elastography methods are becoming the standard of
care as a non-invasive method to assess liver ﬁbrosis
and can be used as an alternative to invasive liver
biopsy.13 Furthermore, to the best of our literature
survey, there have been a limited number of published reports available for predictive factors for the
prevalence of steatosis in a large cohort of chronic
HCV infected patients by using VCTE. Thus, the
present study was conducted to assess the predictive factors of hepatic steatosis diagnosed by VCTE
in chronic HCV infected patients.

2. Methods
This retrospective cross-sectional single-center
study was conducted at a community hospital in
central Massachusetts. A cohort of 158 adult patients
evaluated by VCTE for suspected non-alcoholic fatty
liver disease (NAFLD) was included. The institutional review board approved the study. Patients
with signiﬁcant alcohol consumption, drugs associated with hepatotoxicity, hepatitis B, autoimmune
hepatitis, and primary biliary cirrhosis were
excluded. Steatosis was categorized as S0eS1 (mild)
and S2eS3 (moderate/severe) based on the
controlled attenuation parameter (CAP) score.
The attributes collected were the controlled
attenuation parameter (CAP) score on VCTE, kilopascals (k-Pa), gender, age, body mass index (BMI),

Fig. 1. Regression analysis of the risk factors associated with Hepatic Steatosis: Histogram.
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Fig. 2. Regression analysis of the risk factors associated with Hepatic
Steatosis: PeP plot of regression standardized residual.

hypothyroidism, diabetes mellitus (DM) status,
statin use, HCV status with genotype, transaminases, platelets, apolipoprotein, alpha-2 macroglobulin, hemoglobin A1c (HbA1C), triglycerides,
lipid proﬁle, and anti-hyperglycemic medications.
The results were tabulated and statistically
analyzed using computer software (SPSS version 25
for Windows, SPSS Inc., Chicago, IL). Descriptive
statistics included mean and standard deviation for
quantitative variables and numbers with percentages for qualitative variables. Continuous variables
were assessed using an unpaired t-test, and categorical variables using Chi-square with p < 0.05

were considered statistically signiﬁcant. A multinominal logistic regression analysis was done to
study the relationship between the CAP score
(dependent variable) and signiﬁcant covariates (independent variables). For this purpose, ﬁrstly, a null
model was created to compute an intercept (the
mean value of the dependent variable when all the
independent variables are equal to zero) and a ﬁnal
model (where the dependent variable was calculated as a function of all the independent variables
combined). Secondly, the null model was tested for
goodness-of-ﬁt by nesting it in the ﬁtted model to
ensure validity. For this, a pseudo-R- square was
calculated by three different models. The model
ﬁtting criteria used was 2 log-likelihood (LL),
tested by the above methodology. An LL-based
pseudo-R- square was measured to compare the LL
of the estimated model and the LL of the null model.
There were ﬁve variables used in the regression
analysis. Hepatic steatosis was the dependent variable, and HCV, DM, Obesity, and DM þ HCV were
the independent variables.

3. Results
Of the 158 patients analyzed, 22 met our exclusion
criteria. Therefore, our study population consisted
of 136 patients and was analyzed using their demographic information and CAP scores (see Figs. 1
and 2).
In comparison to CAP grade: S0eS1 (mild steatosis), patients with grade S2eS3 (moderate/severe
steatosis) had a higher mean BMI: 32.46 as
compared to 27.05 (p ¼ 0.001), higher mean ﬁbrosis
raw score (k-Pa): 14.94 as compared to 8.82
(p ¼ 0.009) (Table 1).

Table 1. Study subjects (continuous variables).
Characteristics

Steatosis
(CAP grade)

N

Mean

Std. Dev

Mean
Difference

p-value

AGE

S0 e S1
S2eS3
S0 e S1
S2eS3
S0 e S1
S2eS3
S0 e S1
S2eS3
S0 e S1
S2eS3
S0 e S1
S2eS3
S0 e S1
S2eS3

65
71
65
71
65
71
63
65
43
33
42
32
46
54

50.52
53.56
27.05
32.46
8.82
14.94
25.73
25.94
157.81
145.76
29.24
30.66
35.74
28.11

13.077
12.682
4.368
5.850
12.096
14.606
16.872
19.358
39.530
56.851
9.894
14.043
27.928
21.339

3.040

0.171

5.419

0.001*

6.128

0.009*

0.208

0.948

87.944

0.263

1.418

0.612

7.628

0.125

BMI
KPA (ﬁbrosis)
Raw Score
Platelets
Apolipoprotein
a 2- macroglo
bulin
Triglycerides
p < 0.05.

Table 2. Study subjects (categorical variables).
Patient Characteristics

S0eS1 (mild)

S2eS3 (mod/severe)

Total

Chi-square

p-value

5
7.0%
17
23.9%
49
69.0%

25
18.4%
50
36.8%
61
44.9%

36.369

0.0001*

6.088

0.014*

28
39.4%
43
60.6%

41
30.1%
95
69.9%
0.006

0.938

69
97.2%
2
2.8%

133
97.8%
3
2.2%
9.080

0.028*

30
42.3%
15
21.1%
13
18.3%
13
18.3%

74
54.4%
22
16.2%
19
14.0%
21
15.4%

Obesity
Normal
BMI:18.5e24.9 kg/m2
Overweight
25e29.9
Obesity
>30

20
30.8%
33
50.8%
12
18.5%
Diabetic status
13
20.0%
52
80.0%
HIV
64
98.5%
1
1.5%
Comorbidities
44
67.7%
7
10.8%
6
9.2%
8
12.3%

Diabetes Mellitus (DM)
Non-DM

Negative
Positive

Hepatitis C
Hepatitis C þ DM
DM
No Hepatitis C or diabetes
p < 0.05.

Obesity (p-0.0001*), DM (p-0.014*), and active
comorbidities such as HCV, concomitant HCV with
DM (p-0.028*) were signiﬁcantly different between
study groups viz. S0eS1 (mild) and S2eS3 (moderate/severe) (Table 2). Row statistic for comorbidities
in Table 2 further showed that 40% of patients with
only hepatitis C, 68% of hepatitis C patients with
DM, 68% with DM and, 61% non-hepatitis C, nonDM patients (p-0.028*) had moderate to severe hepatic steatosis.
Table 3. HCV genotype and steatosis (% calculated against entire
sample size).
HCV Genotype

S0eS1

S2eS3

1
2
3
4
6

29 (36.7%)
1 (0.012%)
9 (0.11%)
3 (0.03%)
1 (0.012%)

24 (30.3%)
3 (0.03%)
6 (0.07%)
2 (0.02%)
1 (0.012%)

Chi square - 1.6645.
p value - 0.79.

On the assessment of steatosis based on the genotype of HCV, we found that most patients with
steatosis were in patients with HCV genotype 1
(Table 3). The distribution of severity of mild and
moderate/severe steatosis was similar for each genotype (p ¼ 0.79).
A null model (Table 4) showed a strong relationship between comorbidities and the dependent
variable: steatosis. The degrees of freedom (df) were
24 (p ¼ 0.0001). For the goodness of ﬁt testing,
multiple pseudo-R2 values (Table 5) were compared
for the same predicted outcome (CAP score),
namely, Cox and Snell value- 0.479, Negelkerke
value of 0.520, and McFadden 0.257. The highest
value in the Negelkerke model predicted that all
independent variables combined caused a 52%
change in the dependent variable.
The standard beta coefﬁcient results of the risk
factors associated with hepatic steatosis in multiple
regression analysis depicted that obesity class had a

Table 4. Model summary analysis of the risk factors associated with Hepatic Steatosis.
Model Summary
Model

Model ﬁtting criteria:

Likelihood Ratio tests

2 log-likelihood

Chi-square

Final model
113.377
74.882
a. Predictors: (Constant), Hepatitis C +DM, Obesity Class, DM, and Hepatitis C.

df

sig.

24

0.0001
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Table 5. Showing various models tested for goodness of ﬁt.
Pseudo-R2
Cox and Snell
Nagelkerke
McFadden

0.479
0.520
0.257

statistically signiﬁcant relationship with steatosis
among all other variables. Furthermore, it showed
that each obesity class increase was associated with
steatosis by 50.8 units, as depicted in Table 6.
The ﬁndings described in Table 7 showed that the
2 LL in patients with only HCV and HCV with DM
revealed that omitting the effect of obesity resulted
in zero degrees of freedom (df 0). It appeared that
the initial association of patients with HCV and
HCV þ DM and moderate/severe hepatic steatosis
was confounded by underlying obesity in the patients. Once the variable was controlled for, the association ceased to exist. Obesity independently had
a signiﬁcant association with hepatic steatosis (chisquare value 52, df 12). Interestingly, DM independently predicted a weak association with steatosis
(chi-square value 0.825, df 3).

4. Discussion
Chronic infection with HCV is one of the leading
causes of cirrhosis and hepatocellular carcinoma.
Surveillance of HCV patients is an essential strategy
to prevent liver-related mortality, including the pre/
post-antiviral
treatment
states.
Ultrasound

elastography techniques are emerging as crucial
methods in assessing liver diseases, given their
rapid, non-invasive, and cost-effective characteristics. VCTE measures liver stiffness, and the ultrasonic attenuation through the embedded CAP
provides the clinician a tool for assessing ﬁbrosis,
cirrhosis, and steatosis in a non-invasive manner.
Moreover, standardized liver stiffness values enable
the proper staging of underlying ﬁbrosis, facilitating
accurate identiﬁcation of patients at high risk for
complications and early intervention to prevent
progression. In addition, VCTE is a valuable technique in evaluating liver ﬁbrosis before HCV therapy. VCTE is currently not readily available at all
centers despite gaining worldwide popularity.
The present study comprises a cohort of 136 adult
patients with suspected NAFLD. It evaluated the
relationship of various clinical factors associated
with moderate/severe liver steatosis identiﬁed by
the novel CAP score. In our study, we found the
mean values of BMI (p-0.001), k-Pa (ﬁbrosis) raw
score (p-0.009) to be signiﬁcantly different between
study groups viz. S0eS1 (mild) and S2eS3 (moderate/severe).
The BMI, diabetes, and hepatitis C status of the
cohort enrolled in our study differed signiﬁcantly
between study groups; S0eS1 (mild) and S2eS3
(moderate/severe). Identiﬁcation of factors related
to liver steatosis before treatment might help select
patients that could need a careful follow-up even
after sustained virological response to monitoring
liver ﬁbrosis progression due to additional

Table 6. Standard Beta coefﬁcient results of the risk factors associated with Hepatic Steatosis.
Model

Unstandardized Coefﬁcients

Standardized Coefﬁcients

Beta

Std. Error

Beta

17.076
5.44
7.09
10.2

-0.070
0.508
0.116
0.097

Hepatitis C
11.357
Obesity
37.152
DM
9.088
Hepatitis C+DM
10.729
a. Dependent Variable: Steatosis.

T

Sig.

-0.665
6.823
1.281
1.042

0.507
0.0001
0.203
0.299

Table 7. Results of likelihood ratio tests of the risk factors associated with hepatic steatosis on multivariate regression analysis.
Effect

Model Fitting Criteria
2 Log Likelihood
Reduced Model

Intercept
Gender
Obesity Class
Hepatitis C
DM
Hepatitis C þ DM

113.377a
118.582
165.619
113.377a
114.202
113.377a

Likelihood Ratio Tests
of

Chi-Square

df

Sig.

0.000
5.206
52.242
0.000
0.825
0.000

0
3
12
0
3
0

.
0.157
0.000
.
0.843
.

The chi-square statistic is the difference in 2 log-likelihoods between the ﬁnal and reduced models. The reduced model is formed by
omitting an effect from the ﬁnal model. The null hypothesis is that all effect parameters are 0.
a
This reduced model is equivalent to the ﬁnal model because omitting the effect does not increase the degrees of freedom.

metabolic factors and other extrahepatic complications such as cardiovascular outcomes. Currently,
most guidelines suggest that patients with advanced
ﬁbrosis should periodically be monitored in the
outpatient clinic even after sustained virological
response.15,16 However, those who present only with
moderate/severe steatosis and the related factors
identiﬁed in this study, even with no ﬁbrosis, may
still be required to follow up regularly until clear
evidence is available regarding metabolic factors
and the related outcomes in patients who achieved
sustained virological response. Recently Serfaty
et al. suggested an algorithm where patients who
still had metabolic factors such as high BMI or DM
should be followed annually with non-invasive
markers of ﬁbrosis.17
In our study, the log-likelihood ratio measured the
regression of each selected independent variable
individually, adjusting for the interplay of obesity in
hepatitis C patients and omitting effects of the same
on the outcome (hepatic steatosis). Here, we interestingly found that the chi-square statistic was 0 for
patients with hepatitis C when adjusted for confounding, indicating that active infection did not
play a role in hepatic steatogenesis directly.
Findings like our study have been previously reported. Motamed et al., in their analysis of 5052
subjects, found a signiﬁcant positive correlation
between serum fatty liver index (FLI) and NAFLD
(AUC ¼ 0.8656, 95% CI 0.8548e0.8764); the ﬁndings
were conﬁrmed by binary regression. FLI was
highly associated with NAFLD, to the point that
even a one-unit increase in FLI increased the chance
of NAFLD occurrence by 5.8% and showed good
predictive performance in the diagnosis of
NAFLD.18 Additionally, this is similar to Dehnavi
et al., who analyzed 212 patients with NAFLD and
found that FLI was signiﬁcantly associated with
NAFLD (OR ¼ 1.062, 95%CI 1.042e1.082, p < 0.001),
and that mean FLI, BMI, WC, TG, and GGT were all
signiﬁcantly higher in NAFLD patients as compared
to non-NAFLD participants, and that a one-unit
increase in FLI elevated the chance of developing
NAFLD by 6.2%.19
Although this study was not designed to hypothesize about the pathophysiological pathways
of steatosis in HCV patients, it is possible to
speculate that there may be a synergy between the
already known effect of HCV on metabolic pathways in patients with a higher BMI, leading to a
higher prevalence of steatosis in this group. Thomopoulos et al. reported that steatosis in HCV
patients is higher than in HBV patients, maybe due
to the HCV viral impact on metabolic pathways
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leading to insulin resistance and metabolic syndrome, usually absent in HBV patients.14 Thereby,
we could hypothesize that VCTE should be used
for non-hepatitis C patients with long-standing
type 2 diabetics or obese patients with multiple
comorbidities to screen for steatosis. We need
further studies to recommend whether VCTE
could be included in the regular DM screening like
an eye exam, foot exam, and BP/Lipid proﬁle
management. A screening test that primary care
physicians can order.
A possible question for future prospective studies
is if a patient has achieved sustained viral response
(SVR) with directly-acting-antiviral (DAA) treatment, should they still be monitored with serial
VCTE if they have certain risk factors like obesity
and DM to prevent progression of steatosis to
cirrhosis.
Other studies have reported similar ﬁndings.
Siddiqui et al. performed a prospective study of 393
adults with NAFLD who underwent VCTE within
one year of liver histology and found that the CAP
value is positively associated with the severity of
hepatic steatosis. The cross-validated AUROC is
76% for classifying patients with 5% steatosis on
histology.20 Eddowes et al. evaluated 450 patients
and assessed the diagnostic accuracy of CAP and
liver stiffness measurement against liver biopsy and
found that CAP by TE is an accurate non-invasive
method for assessing liver steatosis in patients with
NAFLD with an AUROC of 0.87 (95% CI 0.82e0.92),
the sensitivity of 0.80, and speciﬁcity of 0.83.21
Although liver biopsy is the gold standard to
detect ﬁbrosis and liver steatosis, it cannot be used
as a screening tool and follow-up of patients with
chronic liver disease due to its invasive nature.
Notwithstanding, other non-invasive methods
have been developed to diagnose steatosis and
quantify fat.22e25 Among image devices, ultrasonography is the most frequently used method for
liver imaging, and steatosis can be assessed by
comparing parenchymal echogenicity with kidney
echogenicity.26 The CAP score can be widely
applied to both diagnose and quantify liver steatosis in HCV-infected patients helping to identify
those that might need further follow-up regarding
metabolic optimization to help preclude liver disease progression.27e30
4.1. Limitations of the study
The predominant genotype (GT) of our study was
GT 1, which has been described previously to predispose metabolic syndrome. We did not sub-
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stratify for genotype during the regression analysis
in our analysis. We hence cannot comment on
which genotype independently attributed to hepatic
steatosis when controlled for obesity.
We have not presented data on the results of the
CAP score after these patients achieved SVR with
DAA. It would be intriguing to see an improvement
in the steatosis severity after treatment.
4.2. Strengths of the study
Our dataset predominantly existed of patients
with HCV. However, despite a smaller sample size
of non-HCV patients, we could still detect a statistical difference and further reproduce it on regression analysis.

5. Conclusion
Our study demonstrates that hepatic steatosis is
independently associated with metabolic parameters like obesity and DM. The most signiﬁcant risk
factor for steatosis in untreated hepatitis C patients
is their BMI. The management of obesity in patients
with HCV may be necessary to reduce the risk of
steatosis progression and improve their steatosis
score.
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